Skip to content

Journal of Psychopharmacology

ISSN 0269-8811, 1461-7285

521 papers in the library · 34,708 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.

Journal of Psychopharmacology August 1, 2024 James Jonathan Rucker, Claire T. Roberts, Mathieu Seynaeve et al. 32 citations

To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), in healthy participants. In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its...

Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights.

Journal of Psychopharmacology August 1, 2024 Luke Baxter, Cheneal Puljević, Tim Piatkowski et al. 3 citations

The recreational use of LSD, a synthetic psychedelic drug, has surged in recent years, coinciding with a renewed research focus on its potential psychotherapeutic properties. This study aims to describe the experiences and perceptions of individuals engaging in LSD use for the first time, derived from a large international sample. This study utilised 2018 Global Drug Survey data collected from...

Chronic Cannabis users exhibit altered oscillatory dynamics and functional connectivity serving visuospatial processing.

Journal of Psychopharmacology August 1, 2024 Camilo A Castelblanco, Seth D Springer, Mikki Schantell et al.

Cannabis is the most widely used psychoactive drug in the United States. While multiple studies have associated acute cannabis consumption with alterations in cognitive function (e.g., visual and spatial attention), far less is known regarding the effects of chronic consumption on the neural dynamics supporting these cognitive functions. We used magnetoencephalography (MEG) and an established...

A framework for assessment of adverse events occurring in psychedelic-assisted therapies

Journal of Psychopharmacology July 31, 2024 Roman Palitsky, Deanna M Kaplan, John Perna et al. 32 citations

Objective: Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assessment of adverse events (AEs) in PAT research has lagged. Current AE reporting standards in PAT trials are poorly calibrated to features of PAT that distinguish it from other treatments, leaving many potential AEs unassessed. Methods: A...

DOI: 10.1177/02698811241265756 (opens in new tab) Dosing Psychosocial Adverse effect Protocol science +6

From chaos to kaleidoscope: Exploring factors in psychedelic self-treatment for mental health conditions.

Journal of Psychopharmacology July 29, 2024 Claire Walker, Timothy Piatkowski, Jason Ferris et al. 4 citations

INTRODUCTION: This study explores how individuals self-treat psychiatric conditions with psychedelics outside medical guidance bridging the gap in understanding unregulated therapeutic use. AIMS: The primary objective was to extract specific factors underlying the effects of psychedelics, exploring their relationship with the need for medication, particularly for mental health conditions like...

DOI: 10.1177/02698811241265762 (opens in new tab) Full text (opens in new tab) Mental-health Psychedelics Self-treatment Depression-anxiety +1

Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile “the great entactogen—empathogen debate”

Journal of Psychopharmacology July 28, 2024 Kurt Stocker, Matthias E. Liechti 15 citations

Science on methylenedioxymethamphetamine (MDMA) and MDMA-like substances is faced with the unique situation that this class of psychoactive agents is referred to with two basic names for its effects on the mind: empathogens and entactogens. Empathogen usually refers to the prosocial, empathetic, and openness properties of MDMA, while entactogen usually refers to the introspective and...

DOI: 10.1177/02698811241265352 (opens in new tab) MDMA Ecstasy Introspection Openness to experience +3

The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms.

Journal of Psychopharmacology July 1, 2024 Mariusz Papp, Piotr Gruca, Ewa Litwa et al. 15 citations

The highly selective 5-HT1A serotonin receptor "biased" agonists NLX-101 and NLX-204 display, like ketamine, potent and efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model with systemic (i.p.) administration. They rapidly (within 1 day) reverse anhedonia (i.e., CMS-induced sucrose consumption deficit), attenuate working memory deficit (novel object...

Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study

Journal of Psychopharmacology June 18, 2024 Kim Hoffman, Alissa Bazinet, Kellie Pertl et al. 14 citations

Background: Voter initiatives in Oregon and Colorado authorize legal frameworks for supervised psilocybin services, but no measures monitor safety or outcomes. Aims: To develop core measures of best practices. Methods: A three-phase e-Delphi process recruited 36 experts with 5 or more years’ experience facilitating psilocybin experiences in various contexts (e.g., ceremonial settings,...

DOI: 10.1177/02698811241257839 (opens in new tab) Psilocybin Delphi method Thematic analysis Applied psychology +2

Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research

Journal of Psychopharmacology June 14, 2024 Vince Polito, Paul Liknaitzky 16 citations

Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. In this rapid review, we aimed to evaluate the strength of evidence for a placebo explanation of the reported effects of microdosing. We conducted a PubMed search for all studies investigating psychedelic microdosing...

DOI: 10.1177/02698811241254831 (opens in new tab) Psilocybin Hallucinogen Placebo Expectancy theory +2

Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems.

Journal of Psychopharmacology June 1, 2024 Emily M Gent, Joshua W. Bryan, Maisy A Cleary et al. 20 citations

Alcohol use disorder (AUD) is a major public health issue, posing harmful consequences for individuals and society. Recent advances in addiction research have highlighted the therapeutic potential of ketamine-assisted therapy for AUD. However, the exact mechanisms underlying its effectiveness remain unknown. This double-blind, pilot study aimed to investigate esketamine combined with...

Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ)

Journal of Psychopharmacology May 1, 2024 Max Wolff, Ricarda Evens, Lea J. Mertens et al. 34 citations

Background: Therapeutic and salutogenic effects of psychedelic drugs have been attributed to psychotherapeutic or psychotherapy-like processes that can unfold during the acute psychedelic experience and beyond. Currently, there are no psychometric instruments available to comprehensively assess psychotherapeutic processes (as conceptualized by empirical psychotherapy research) in the context of...

DOI: 10.1177/02698811241249698 (opens in new tab) Clinical psychology Context archaeology Psychotherapist

The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis.

Journal of Psychopharmacology May 1, 2024 Arman Shafiee, Razman Arabzadeh Bahri, Mohammad Ali Rafiei et al. 21 citations Retracted

Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways within the brain. Integrated review and analysis of different studies in this field. A systematic search was conducted across international databases including Embase, Scopus, Web of Science, and PubMed from inception to 9 July 2023. Eligibility...

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.

Journal of Psychopharmacology May 1, 2024 Thomas Knuijver, Rob Ter Heine, Arnt Schellekens et al. 15 citations

Ibogaine is a hallucinogenic drug that may be used to treat opioid use disorder (OUD). The relationships between pharmacokinetics (PKs) of ibogaine and its metabolites and their clinical effects on side effects and opioid withdrawal severity are unknown. We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. The study was performed in 14...

The neural oscillations serving task switching are altered in cannabis users.

Journal of Psychopharmacology May 2024 Kellen M McDonald, Mikki Schantell, Lucy K Horne et al.

Regular cannabis is known to impact higher-order cognitive processes such as attention, but far less is known regarding cognitive flexibility, a component of executive function. Moreover, whether such changes are related to aberrations in the neural oscillatory dynamics serving flexibility remains poorly understood. Quantify the neural oscillatory dynamics serving cognitive flexibility by...

DOI: 10.1177/02698811241235204 (opens in new tab) Full text (opens in new tab) Cannabis Magnetoencephalography Prefrontal cortex Task switching +1

Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice

Journal of Psychopharmacology April 28, 2024 Xiangting Zhao, Yingjie Du, Yishan Yao et al. 53 citations

Background: Psilocybin offers new hope for treating mood disorders due to its rapid and sustained antidepressant effects, as standard medications require weeks or months to exert their effects. However, the mechanisms underlying this action of psilocybin have not been identified. Aims: To investigate whether psilocybin has rapid and sustained antidepressant-like effects in mice and investigate...

Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks.

Journal of Psychopharmacology April 23, 2024 Evan Cole Lewis, Alexandria Jaeger, Manesh Girn et al. 6 citations

Functional seizures (FS), the most common subtype of functional neurological disorder (FND), cause serious neurological disability and significantly impact quality of life. Characterized by episodic disturbances of functioning that resemble epileptic seizures, FS coincide with multiple comorbidities and are treated poorly by existing approaches. Novel treatment approaches are sorely needed....

DOI: 10.1177/02698811241248395 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Functional neurological disorders Mental health treatment Alternative medicine

Psychedelics and the ‘inner healer’: Myth or mechanism?

Journal of Psychopharmacology April 12, 2024 Joseph Peill, Miriam Marguilho, David Erritzøe et al. 16 citations

Background: Reference to an intrinsic healing mechanism or an ‘inner healer’ is commonplace amongst psychedelic drug-using cultures. The ‘inner healer’ refers to the belief that psychedelic compounds, plants or concoctions have an intrinsically regenerative action on the mind and brain, analogous to intrinsic healing mechanisms within the physical body, for example, after sickness or injury....

DOI: 10.1177/02698811241239206 (opens in new tab) Telos Automatic Psychedelic-therapy Natural-healing +2

Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.

Journal of Psychopharmacology April 1, 2024 Nelson B Rodrigues, David C J Chen-Li, Joshua D. Di Vincenzo et al. 12 citations

Converging lines of evidence indicate that ketamine is a rapid antidepressant for individuals with treatment-resistant depression. Hitherto, no reliable a priori predictors of ketamine response have been reported. Pharmacogenetic biomarkers have yielded mixed results regarding potential candidate genes associated with ketamine's biochemistry as reliable predictors of response. No studies have...

Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression

Journal of Psychopharmacology March 22, 2024 Tommaso Barba, David Erritzøe, Meg J. Spriggs et al. 26 citations

Background: There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. However, due to the lack of safety data on combining psilocybin with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and concerns that there may be a negative interaction on efficacy, participants enrolling in...

Psychiatric risks for worsened mental health after psychedelic use.

Journal of Psychopharmacology March 4, 2024 Alessia Marrocu, Hannes Kettner, Brandon Weiss et al. 51 citations

Background: Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increase in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem to be rare; however, studies are limited...

DOI: 10.1177/02698811241232548 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Psychedelic treatment Therapeutic psychedelics Therapeutic promise +16

MDMA enhances positive affective responses to social feedback.

Journal of Psychopharmacology March 1, 2024 Anya K. Bershad, David T Hsu, Harriet de Wit 9 citations

The prosocial compound ± 3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative that has shown promise as an adjunct to psychotherapy in the treatment of post-traumatic stress disorder. MDMA increases positive responses to social images, and it has been suggested that the ability of MDMA to positively bias social perception may underlie its therapeutic efficacy as a psychotherapy...

DOI: 10.1177/02698811231224153 (opens in new tab) Full text (opens in new tab) MDMA Social acceptance Social feedback Social rejection

Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.

Journal of Psychopharmacology January 27, 2024 Jessica Barbut Siva, Tommaso Barba, Hannes Kettner et al. 29 citations

Background: There is growing evidence for the therapeutic effects of psychedelics. However, it is still uncertain how these drugs interact with serotonergic antidepressants (serotonin reuptake inhibitors (SRIs)). Objective: This study explores the interaction between psychedelics and SRIs in terms of therapeutic effects. The objective is to compare acute psychedelic effects and subsequent...

DOI: 10.1177/02698811231224217 (opens in new tab) Full text (opens in new tab) Psychedelics Antidepressants Mental health Drug interactions +1

Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins

Journal of Psychopharmacology January 12, 2024 Antonin Rouaud, Gregor Hasler, Abigail E. Calder 36 citations

Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly involves ingesting sub-threshold doses of lysergic acid diethylamide (LSD), psilocybin, or other psychedelic drugs 2–4 times a week for at least several weeks, but potentially months or years. Concerningly, both LSD and psilocybin share structural...

Psychological and physiological effects of extended DMT.

Journal of Psychopharmacology 2024 Lisa Luan, Emma Eckernäs, Michael Ashton et al. 41 citations

N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that induces a rapid and transient altered state of consciousness when inhaled or injected via bolus administration. Its marked and novel subjective effects make DMT a powerful tool for the neuroscientific study of consciousness and preliminary results show its potential role in treating mental health conditions. In a within-subjects,...

Older adults in psychedelic-assisted therapy trials: A systematic review

Journal of Psychopharmacology 2024 Lisa Bouchet, Zachary Sager, Antoine Yrondi et al. 22 citations

Background: Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety,...